The Quest for an Ideal Neoadjuvant Systemic Therapy in Cisplatin-Ineligible Patients with Muscle-Invasive Localized Urothelial Carcinoma

Oncologist. 2019 May;24(5):580-583. doi: 10.1634/theoncologist.2019-0161. Epub 2019 Mar 29.

Abstract

This commentary reviews current progress in neoadjuvant immunotherapy for muscle‐invasive localized urothelial carcinoma, highlighting opportunities and challenges with recent neoadjuvant immunotherapy trials.

Publication types

  • Comment

MeSH terms

  • Carcinoma, Transitional Cell*
  • Cisplatin
  • Humans
  • Neoadjuvant Therapy
  • Urinary Bladder Neoplasms*
  • Urologic Neoplasms*

Substances

  • Cisplatin